Resources

Video resources

A story of wonder

A testimonial from Ashley, a mother and caregiver, about her daughter Autumn and their journey from diagnosis to treatment with RETHYMIC and beyond.

How RETHYMIC is manufactured

A look at each stage of the engineering process of RETHYMIC.

Understanding the congenital athymia patient journey

An edited recording of a webinar featuring a caregiver and a healthcare provider about the treatment journey and their partnership. This webinar was originally available as part of the Enzyvant CONNECT support program, which is now known as RETHYMIC Connect™.

Downloadable resources

Understanding and Living With Congenital Athymia

A guide to congenital athymia, from diagnosis to creating a care plan.

Download

A Caregiver’s Guide to RETHYMIC

A guide to help you better understand what RETHYMIC is, how it may help your child with congenital athymia, and more.

Download

The Road to RETHYMIC

A guide to help caregivers navigate the different steps of the congenital athymia treatment journey, from diagnosis to receiving RETHYMIC and beyond.

Download

Organizations that can help caregivers and their families

Several organizations provide valuable support and education to children with immune system diseases and their families.

Jeffrey Modell logo

Jeffrey Modell Foundation is a global patient organization devoted to early and precise diagnoses, meaningful treatments, and ultimately, cures for primary immunodeficiencies (PIs).

Global Genes logo

Global Genes is dedicated to eliminating the burdens and challenges of rare diseases for patients and families.

Immune Deficiency Foundation logo

The Immune Deficiency Foundation is dedicated to improving the diagnosis, treatment, and quality of life of people affected by PIs by fostering a community empowered by advocacy, education, and research.

NORD logo

The National Organization for Rare Disorders is a patient advocacy organization dedicated to individuals with rare diseases and the organizations that serve them.

rethymic connect logo
RETHYMIC Connect provides support and resources to children with congenital athymia and their caregivers.
Get support today
Indication and Important Safety Information
Important Safety Information

Infection Control: Immune reconstitution sufficient to protect from infection usually develops between 6-12 months after treatment with RETHYMIC. For some children, it may take up to 2 years. Taking medications that prevent infection and other infection control measures, such as hand washing and isolation, should be continued until your child’s doctor confirms that immune function has been reconstituted through immune tests and the criteria for discontinuing certain medications have been met. Immediately report signs and symptoms of infection, such as fever, to your child’s doctor.

Graft versus Host Disease (GVHD): RETHYMIC may cause or make pre-existing GVHD worse. Your child will be monitored for GVHD and treated if needed. Symptoms of GVHD may include fever, rash, swollen lymph nodes, inflammation of the digestive system, and/or diarrhea.

Autoimmune Disorders: Autoimmune-related side effects (when your immune system attacks healthy cells by mistake) occurred in patients treated with RETHYMIC. These included low platelets, white blood cells, or red blood cells; protein in the urine; hair loss; poor thyroid function; inflammation of the liver, joints, or spinal cord; loss of pigment in the skin, eyes and hair; overactive thyroid function; and loss of function of the ovaries. Your doctor will monitor your child regularly.

Kidney Disease: Children with kidney disease have a higher risk of death when treated with RETHYMIC.

Cytomegalovirus (CMV) Infection: In clinical studies, 4 out of 4 patients with CMV infection prior to treatment with RETHYMIC died.

Cancer: Due to your child’s weakened immune system, there is an increased risk of developing blood cancer. Your child’s doctor will monitor your child through testing for Epstein-Barr virus and CMV, which are two viruses that can cause cancer.

Transmission of Serious Infections and Transmissible Infectious Diseases: Because RETHYMIC is made from human tissue, and animal products are used in the manufacturing process, transmission of infectious diseases may occur.

Vaccine Administration: Notify your child’s doctor to evaluate your child’s immune status before receiving vaccinations. Live virus vaccines should not be given until the doctor determines that your child has met criteria for and received inactivated vaccines.

Anti-HLA Antibodies: Before receiving RETHYMIC, your child will be tested for HLA antibodies, which are proteins that may be present in your child’s blood. If your child has these antibodies, your child should receive RETHYMIC from a specific donor, which will be determined by your child’s doctor.

HLA Typing: If your child received a hematopoietic cell transplantation (HCT) or a solid organ transplant, testing to match your child with RETHYMIC from a compatible donor is required. Children who have received an HCT are at an increased risk of developing GVHD after RETHYMIC if the HCT donor does not fully match with RETHYMIC.

Deaths: Of the 105 children who participated in the clinical studies, 29 patients died, including 23 in the first year after implantation of RETHYMIC.

The most common side effects are high blood pressure, cytokine release syndrome, rash, low magnesium, decrease in kidney function, low platelets, and GVHD.

These are not all the possible side effects of RETHYMIC. Talk to your child’s doctor about any side effect that bothers your child or does not go away.

You are encouraged to report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/safety/medwatch.

Indication

RETHYMIC® is indicated for immune reconstitution in pediatric patients with congenital athymia.

RETHYMIC is not for use in patients who have been diagnosed with severe combined immunodeficiency (SCID).

sumitomo logo

Sumitomo Pharma is a trademark of Sumitomo Pharma Co., Ltd., used under license. SUMITOMO PHARMA is a trademark of Sumitomo Pharma Co., Ltd., used under license. SUMITOMO is a registered trademark of Sumitomo Chemical Co., Ltd., used under license. Sumitomo Pharma America, Inc. is a U.S. subsidiary of Sumitomo Pharma Co., Ltd. RETHYMIC ®, RETHYMIC Connect™, and its logos are trademarks of Sumitomo Pharma Switzerland GmbH. © 2024 Sumitomo Pharma Switzerland GmbH. All rights reserved. RET-US-0380-24    11/2024